Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental and clinical studies with active specific immunotherapy.

P O Livingston1

  • 1Memorial Sloan-Kettering Cancer Center, New York, New York 10021.

Progress in Clinical and Biological Research
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.

Cancer immunology, immunotherapy : CII·2005
Same author

Clinical results using biochemotherapy as a standard of care in advanced melanoma.

Melanoma research·2002
Same author

Vaccines for melanoma: translating basic immunology into new therapies.

The Lancet. Oncology·2002
Same author

Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.

Journal of cancer research and clinical oncology·2002
Same author

Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.

International journal of cancer·2001
Same author

Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial.

Proceedings of the National Academy of Sciences of the United States of America·2001

Developing effective melanoma vaccines is crucial for active specific immunotherapy. Inducing immune responses against melanoma antigens like ganglioside GM2 shows promise for treating cancer and preventing recurrence.

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • Identifying immunogenic melanoma antigens is key for vaccine construction.
  • Murine monoclonal antibodies and melanoma specimen extraction may define new antigens.
  • Expression profiling on normal tissues is essential to avoid off-target effects.

Purpose of the Study:

  • To explore factors in constructing melanoma vaccines for clinical testing.
  • To evaluate strategies for defining and utilizing immunogenic melanoma antigens.
  • To assess the potential of active specific immunotherapy in treating and preventing melanoma recurrence.

Main Methods:

  • Utilizing reactive antibodies for melanoma antigen identification.
  • Employing purified antigens or whole tumor cells/fractions for immunization.

Related Experiment Videos

  • Using experimental models to optimize vaccine adjuvants, delivery vehicles, and suppressor cell treatments.

    • Main Results:

    • Consistent induction of high-titer antibody responses against ganglioside GM2 has been achieved.
    • Purified antigens allow for increased dosage and improved immunogenic presentation.
    • Whole tumor cells/fractions may elicit responses against previously unknown antigens.

    Conclusions:

    • Active specific immunotherapy shows potential for treating malignant melanoma.
    • Successful immunization against multiple melanoma antigens could open doors for clinical trials.
    • Further research aims to establish immunotherapy's role in preventing recurrence and treating measurable cancer.